Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.

By Wolfgang Löscher, Heidrun Potschka. Progress in neurobiology, 2005

613 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Blood-brain barrier pathophysiology in traumatic brain injury (2011, background): “The bioavailability of neuroprotective drugs to the brain depends, among other factors, on the activity of xenobiotic efflux transporters residing at the BBB [233].”
Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors (2017, background): “Often, the extrusion of xenobiotics out of the CNS, including therapeutic compounds and their metabolites, is performed by transporters from the ATP-binding cassette family, namely P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-associated proteins (Löscher a”
The blood-brain barrier in Alzheimer's disease (2017, neutral): “…in the human hippocampus, a region involved in learning and memory, but more accelerated degradation in patients with mild cognitive impairment (MCI) compared to age-matched neurologically intact controls, suggesting this phenomenon contributes to early cognitive impairment (Montagne et al., 2015).”
Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions (2006, background): “Drug efflux transporters, such as P-glycoprotein (Pgp), are mainly present on the luminal membrane surface (Loscher and Potschka 2005b).”